Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04050462
Title A Phase II, Randomized, Controlled Trial of Nivolumab in Combination With BMS-986253 or Cabiralizumab in Advanced Hepatocellular Carcinoma (HCC) Patients
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors NYU Langone Health
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.